Skip to main content

Enhancing Laboratory Workflow through Automated Immunoassay Testing: Focus on Chromogranin A

Tracking # 20-1257836

Price not reported

There are no ratings for this course

Learn more
CE Broker Reporting Reported automatically
Method Broadcasted Interactive Event
Dates Contact provider

Course overview

Join this webinar to learn about the possibilities of automated laboratory technologies in biomarker testing. In this webinar, Dr. Peter Kavsak will compare the benefits and limitations of current laboratory-developed tests and newer automated platforms in testing. He will also discuss how automated laboratory technologies have the potential improve test accuracy, laboratory workflow, and the total testing process. Dr. Kavsak will use the chromogranin A (CgA) assay as an example of a biomarker used in the assessment of a complex class of cancers called neuroendocrine tumors (NETs). This timely clinical example will highlight the challenges of biomarker testing in the laboratory, longstanding challenges with standard CgA assays in NET monitoring, and recent indications of a newly approved CgA automated immunoassay. From the discussion, participants will explore the real-world example of the CgA immunoassay to learn about the applications, considerations, and implementation of newer automated platforms in the clinical laboratory.

Subject areas

This course counts toward the state boards and subject areas below.

American Board of Clinical Chemistry

Clinical Chemistry Diplomate

1h Category 1

Molecular Diagnostics Diplomate

1h Category 1

Toxicological Chemistry Diplomate

1h Category 1

Florida Board of Clinical Laboratory Personnel

Clinical Laboratory Director

1h General

Clinical Laboratory Supervisor

1h General

Clinical Laboratory Technician

1h General

Clinical Laboratory Technologist

1h General

Public Health Director

1h General

Public Health Supervisor

1h General

Public Health Technologist

1h General

Disclosure statements

The Association for Diagnostics & Laboratory Medicine (formerly AACC) is dedicated to ensuring balance, independence, objectivity, and scientific rigor in all educational activities. All participating planning committee members and faculty are required to disclose to the program audience any financial relationships related to the subject matter of this program. Disclosure information is reviewed in advance in order to manage and resolve any possible conflicts of interest. The intent of this disclosure is to provide participants with information on which they can make their own judgments.


The following faculty reported financial relationships:


  • Peter Kavsak PhD, FADLM, FCACB, FCCS
  • Honorarium/Speaker Expenses: Abbott, Beckman Coulter, Roche Diagnostics, Siemens Healthcare Diagnostics, Thermo Fisher Scientific
  • Consultant Fee: Abbott, Diagnostics, Siemens Healthcare Diagnostics
  • Grant/Research Support: Abbott, Beckman Coulter, Ortho Clinical Diagnostics, Randox Laboratories, Roche Diagnostics, Siemens Healthcare Diagnostics
  • Board/Committee Membership/Advisory Board: Quidel, Roche Diagnostics, Siemens Healthcare Diagnostics
  • Intellectual Property/Royalty Income: McMaster University has filed patents with Dr. Kavsak listed as an inventor in the acute cardiovascular biomarker field